1. Home
  2. CRSP vs TKC Comparison

CRSP vs TKC Comparison

Compare CRSP & TKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • TKC
  • Stock Information
  • Founded
  • CRSP 2013
  • TKC 1993
  • Country
  • CRSP Switzerland
  • TKC Turkey
  • Employees
  • CRSP N/A
  • TKC N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • TKC Telecommunications Equipment
  • Sector
  • CRSP Health Care
  • TKC Telecommunications
  • Exchange
  • CRSP Nasdaq
  • TKC Nasdaq
  • Market Cap
  • CRSP 5.4B
  • TKC 5.2B
  • IPO Year
  • CRSP 2016
  • TKC 2000
  • Fundamental
  • Price
  • CRSP $54.26
  • TKC $6.04
  • Analyst Decision
  • CRSP Buy
  • TKC
  • Analyst Count
  • CRSP 16
  • TKC 0
  • Target Price
  • CRSP $72.27
  • TKC N/A
  • AVG Volume (30 Days)
  • CRSP 2.9M
  • TKC 630.4K
  • Earning Date
  • CRSP 08-04-2025
  • TKC 08-13-2025
  • Dividend Yield
  • CRSP N/A
  • TKC 3.92%
  • EPS Growth
  • CRSP N/A
  • TKC N/A
  • EPS
  • CRSP N/A
  • TKC 0.27
  • Revenue
  • CRSP $38,050,000.00
  • TKC $4,477,789,455.00
  • Revenue This Year
  • CRSP $28.31
  • TKC $40.02
  • Revenue Next Year
  • CRSP $268.05
  • TKC $28.18
  • P/E Ratio
  • CRSP N/A
  • TKC $8.92
  • Revenue Growth
  • CRSP N/A
  • TKC 1.16
  • 52 Week Low
  • CRSP $30.04
  • TKC $5.54
  • 52 Week High
  • CRSP $71.13
  • TKC $7.63
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 45.78
  • TKC 58.29
  • Support Level
  • CRSP $51.80
  • TKC $5.78
  • Resistance Level
  • CRSP $61.44
  • TKC $6.10
  • Average True Range (ATR)
  • CRSP 2.79
  • TKC 0.09
  • MACD
  • CRSP -0.79
  • TKC 0.03
  • Stochastic Oscillator
  • CRSP 26.14
  • TKC 85.23

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About TKC Turkcell Iletisim Hizmetleri AS

Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.

Share on Social Networks: